Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details)

v3.20.1
Stockholders' Equity and Common Stock Purchase Warrants - Schedule of Noncontrolling Interest (Details) - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
NCI - equity (deficit) - beginning of period $ (161,512)  
Net loss attributable to NCI (810,890) $ (204,072)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan 1,396,707 1,175,466
NCI - equity (deficit) - end of period (814,279) (161,512)
Non-controlling Interest [Member]    
NCI - equity (deficit) - beginning of period (161,512)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan
NCI - equity (deficit) - end of period (814,279) (161,512)
Non-controlling Interest [Member] | Lucid Diagnostics Inc [Member]    
Investment in majority-owned subsidiary 1,812
Net loss attributable to NCI (801,224) (204,072)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan 158,123 40,748
Non-controlling Interest [Member] | Solys Diagnostics Inc. [Member]    
Investment in majority-owned subsidiary 889
Share Subscription Receivable (889)
Net loss attributable to NCI $ (9,666)